XBIO Stock Price, Xenetic Biosciences Inc Quote, Chart

Market Summary

USD4.69-0.03

Market Closed

-0.64%

XBIO Stock Price

View Fullscreen

XBIO RSI Chart

XBIO Valuation

Market Cap

7.2M

Price/Earnings (Trailing)

-1.75

Price/Sales (Trailing)

2.84

EV/EBITDA

0.16

Price/Free Cashflow

-1.76

XBIO Price/Sales (Trailing)

XBIO Profitability

Operating Margin

93.85%

EBT Margin

-659.83%

Return on Equity

-42.21%

Return on Assets

-38.99%

Free Cashflow Yield

-56.94%

XBIO Fundamentals

XBIO Revenue

Revenue (TTM)

2.5M

Rev. Growth (Yr)

37.99%

Rev. Growth (Qtr)

9.95%

XBIO Earnings

Earnings (TTM)

-4.1M

Earnings Growth (Yr)

20.98%

Earnings Growth (Qtr)

-10.98%

Breaking Down XBIO Revenue

Last 7 days

1.5%

Last 30 days

9.6%

Last 90 days

21.8%

Trailing 12 Months

913.0%

How does XBIO drawdown profile look like?

XBIO Financial Health

Current Ratio

11.84

Debt/Equity

0.02

Debt/Cashflow

-19.33

XBIO Investor Care

Shares Dilution (1Y)

1.58%

Diluted EPS (TTM)

-2.73

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.9M	2.2M	2.4M	2.5M
2022	1.4M	1.5M	1.6M	1.7M
2021	571.4K	746.1K	979.4K	1.2M
2020	4.7M	3.3M	1.9M	436.9K
2019	0	0	0	6.2M
2017	4.1M	5.3M	6.4M	7.6M
2016	0	0	0	3.0M
2015	0	0	0	0
2014	0	0	0	0
2013	0	221.9K	78.4K	692.8K
2012	0	0	126.7K	210.1K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Xenetic Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jul 19, 2019	genkin dmitry	acquired	-	-	93,390	-
Mar 14, 2018	genkin dmitry	sold	-	-	-29,452	-

Which funds bought or sold XBIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Feb 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	-14,309	39,504	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	reduced	-26.3	-3,263	3,519	-%
Feb 13, 2024	FMR LLC	sold off	-100	-5.00	-	-%
Feb 13, 2024	MORGAN STANLEY	reduced	-99.66	-1,443	3.00	-%
Feb 12, 2024	Steward Partners Investment Advisory, LLC	unchanged	-	-2,755	6,555	-%
Feb 09, 2024	UBS Group AG	new	-	1,052	1,052	-%
Feb 09, 2024	WELLS FARGO & COMPANY/MN	added	10.00	-11.00	38.00	-%
Feb 07, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Feb 07, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Jan 16, 2024	JTC Employer Solutions Trustee Ltd	unchanged	-	2,000	10,000	-%

Are Funds Buying or Selling XBIO?

Are funds buying XBIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own XBIO

No. of Funds

Unveiling Xenetic Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 18, 2024	cls therapeutics, llc	5.5%	85,000	SC 13D/A
Sep 18, 2023	cls therapeutics, llc	5.5%	85,000	SC 13D/A
Jun 15, 2023	cls therapeutics, llc	5.6%	85,000	SC 13D
Oct 21, 2022	cls therapeutics, llc	9.7%	1,475,000	SC 13G
Dec 21, 2020	intracoastal capital, llc	0.0%	0	SC 13G
Feb 14, 2020	anson funds management lp	-	0	SC 13G/A
Feb 13, 2020	altium capital management lp	0%	0	SC 13G/A
Feb 10, 2020	cvi investments, inc.	0%	0	SC 13G/A
Jan 21, 2020	empery asset management, lp	1.92%	112,745	SC 13G/A
Jan 13, 2020	sabby management, llc	4.99%	287,182	SC 13G/A

Recent SEC filings of Xenetic Biosciences Inc

View All Filings

Date Filed	Form Type	Document
Mar 22, 2024	8-K	Current Report
Mar 21, 2024	10-K	Annual Report
Mar 18, 2024	SC 13D/A	13D - Major Acquisition
Feb 12, 2024	8-K	Current Report

Peers (Alternatives to Xenetic Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.9B	6.8B	-4.35%	-31.01%	-8.68	5.98	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.2B	1.8B	2.23%	-24.84%	-43.61	10.5	76.23%	61.08%
BMRN	17.0B	2.4B	4.87%	-7.82%	101.5	7.03	15.42%	18.43%
INCY	12.4B	3.7B	-9.49%	-25.82%	20.67	3.34	8.87%	75.42%
MID-CAP
APLS	6.9B	396.6M	-6.36%	-28.65%	-12.96	17.28	425.83%	18.94%
BBIO	4.8B	-	-5.56%	77.93%	-7.36	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	0.03%	16.25%	-14.05	12.42	440.80%	-27.84%
ARWR	3.1B	240.7M	-13.61%	-3.16%	-10.6	13.07	-1.03%	-92.09%
ACAD	2.9B	726.4M	-26.61%	-2.10%	-47.61	4.02	40.45%	71.62%
SMALL-CAP
CPRX	1.9B	398.2M	-1.37%	-9.52%	26.21	4.7	85.90%	-14.05%
NVAX	596.2M	983.7M	-16.96%	-52.88%	-1.09	0.61	-50.36%	17.16%
CRBP	400.4M	881.7K	-0.31%	365.37%	-8.98	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-4.49%	31.28%	-1.99	55.23	-54.97%	51.72%
IBIO	7.0M	2.1M	71.19%	77.19%	-0.26	2.14	-13.45%	66.37%

Xenetic Biosciences Inc News

Latest updates

Xenetic Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2017Q4	2017Q3	2017Q2	2017Q1
Revenue	9.9%	672	611	651	606	487	414	417	389	333	349	288	191	151	116	113	-	-	-	-	-	-
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	97.00	59.00	-
Operating Expenses	9.7%	1,928	1,758	1,849	1,521	2,050	1,262	3,104	2,009	2,207	1,725	1,415	1,560	1,371	10,620	1,095	1,288	1,252	-	-	-	-
S&GA Expenses	29.1%	952	737	946	926	857	863	1,026	907	978	945	891	931	881	804	787	928	835	-	-	-	-
R&D Expenses	-4.4%	976	1,021	903	595	1,193	399	2,077	1,101	1,229	780	525	630	491	573	308	360	417	-	-	-	-
EBITDA Margin	7.3%	-6.46*	-6.97*	-7.62*	-8.61*	-9.72*	-10.72*	-11.20*	-12.26*	-14.35*	-17.02*	-22.34*	-29.16*	-	-	-	-	-	-	-	-	-
Interest Expenses	-100.0%	-	92.00	126	54.00	80.00	45.00	16.00	26.00	29.00	28.00	21.00	22.00	21.00	25.00	29.00	51.00	62.00	-10.55	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,918	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-1,350	-	-	-	-10,478	-	-	-	-	-	-	-
EBT Margin	7.3%	-6.60*	-7.12*	-7.77*	-8.71*	-9.82*	-10.79*	-11.27*	-12.34*	-14.44*	-17.11*	-22.46*	-29.33*	-	-	-	-	-	-	-	-	-
Net Income	-11.0%	-1,171	-1,055	-1,050	-856	-1,482	-804	-2,672	-1,593	-1,841	-1,350	-1,106	-1,345	-1,200	-7,560	-953	-1,179	-1,170	-	-	-	-
Net Income Margin	13.8%	-1.63*	-1.89*	-1.94*	-3.02*	-3.84*	-4.45*	-5.01*	-4.34*	-4.86*	-5.11*	-15.03*	-19.36*	-	-	-	-	-	-	-	-	-
Free Cashflow	16.5%	-791	-947	-1,267	-1,100	-748	-1,077	-726	-2,085	-1,456	-1,031	-724	-1,517	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-11.3%	10,605	11,961	12,749	13,716	14,720	15,573	16,468	17,984	19,815	21,285	10,915	11,762	13,179	8,696	19,063	20,625	21,547	22,875	15,633	16,456	14,431
Current Assets	-14.8%	9,587	11,257	12,045	12,871	13,653	14,167	15,376	16,889	18,723	20,581	10,199	11,036	12,370	7,992	9,116	10,678	11,090	12,921	2,389	3,201	1,194
Cash Equivalents	-8.1%	8,983	9,776	10,726	11,995	13,097	13,848	14,927	16,156	18,244	19,703	9,282	10,008	11,528	7,054	8,066	9,367	10,368	12,044	1,034	2,085	638
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	166*	757*	2.00	3.00	3.00	5.00
Goodwill	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,283	3,283	3,283
Liabilities	-24.2%	810	1,068	871	856	1,073	1,051	1,279	1,063	1,421	1,121	966	816	964	788	3,706	4,426	4,334	4,616	5,242	4,938	4,518
Current Liabilities	-24.2%	810	1,068	871	856	1,073	1,051	1,279	1,063	1,421	1,121	958	798	937	788	787	1,507	1,415	1,697	2,318	2,006	1,600
Shareholder's Equity	-10.1%	9,796	10,893	11,878	12,859	13,647	14,522	15,189	16,920	18,394	20,164	9,949	10,946	12,216	7,908	15,358	16,199	17,213	18,259	10,391	11,519	9,913
Retained Earnings	-0.6%	-193,234	-192,062	-191,007	-189,956	-189,099	-187,617	-186,813	-184,140	-182,547	-180,705	-179,354	-178,248	-176,902	-175,702	-168,141	-167,188	-166,008	-164,838	-155,938	-154,560	-153,233
Additional Paid-In Capital	0.0%	208,054	207,978	207,908	207,825	207,770	207,150	207,012	206,072	205,953	205,881	194,320	194,210	194,134	188,628	188,518	188,406	188,240	188,117	171,353	171,103	168,170
Shares Outstanding	0.5%	1,541	1,533	1,533	1,517	1,517	1,432	1,407	1,344	1,344	922	875	875	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	11,319	-	-	-	17,462	-	-	-	6,136	-	-	-	5,343	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	16.5%	-793	-949	-1,269	-1,102	-750	-1,079	-728	-2,087	-1,458	-1,033	-726	-1,519	-953	-1,012	-1,300	-1,000	-1,677	-2,416	-1,050	-1,254	-1,040
Share Based Compensation	-	-	-	-	-	-	-	-	120	113	111	110	76.00	81.00	111	112	166	123	232	234	217	239
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00	-
Cashflow From Financing	-	-	-	-	-	-	-	-	-	-	-	-	-	5,427	-	-	-	1.00	13,426	509*	2,699	-

XBIO Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Revenue
Royalty revenue	$ 2,539,986	$ 1,706,925
Total revenue	2,539,986	1,706,925
Operating costs and expenses:
Research and development	(3,494,765)	(4,770,834)
General and administrative	(3,560,936)	(3,653,999)
Total operating costs and expenses	(7,055,701)	(8,424,833)
Loss from operations	(4,515,715)	(6,717,908)
Other income (expense):
Other income (expense)	25,380	(1,597)
Interest income, net	355,757	167,152
Total other income, net	381,137	165,555
Net loss	$ (4,134,578)	$ (6,552,353)

XBIO Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 8,983,046	$ 13,097,265
Prepaid expenses and other	603,828	556,094
Total current assets	9,586,874	13,653,359
Other assets	1,018,352	1,066,931
Total assets	10,605,226	14,720,290
Current liabilities:
Accounts payable	240,832	287,360
Accrued expenses and other current liabilities	568,753	785,796
Total current liabilities	809,585	1,073,156
Total liabilities	809,585	1,073,156
Commitments and contingencies (Note 13)
Stockholders' equity:
Common stock, $0.001 par value; 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 1,543,385 and 1,519,360 shares issued as of December 31, 2023 and December 31, 2022, respectively; 1,540,684 and 1,516,659 shares outstanding as of December 31, 2023 and December 31, 2022, respectively	1,544	1,520
Additional paid in capital	208,053,935	207,769,904
Accumulated deficit	(193,234,196)	(189,099,618)
Accumulated other comprehensive income	253,734	253,734
Treasury stock	(5,281,180)	(5,281,180)
Total stockholders' equity	9,795,641	13,647,134
Total liabilities and stockholders' equity	10,605,226	14,720,290
Series B Preferred Stock [Member]
Stockholders' equity:
Preferred stock, value	1,804	1,804
Series A Preferred Stock [Member]
Stockholders' equity:
Preferred stock, value	$ 0	$ 970

About Xenetic Biosciences Inc

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

CEO	Mr. Jeffrey F. Eisenberg Esq.
WEBSITE	xeneticbio.com
INDUSTRY	Biotechnology
EMPLOYEES	4

Xenetic Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Xenetic Biosciences Inc? What does XBIO stand for in stocks?

XBIO is the stock ticker symbol of Xenetic Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Xenetic Biosciences Inc (XBIO)?

As of Wed Apr 10 2024, market cap of Xenetic Biosciences Inc is 7.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XBIO stock?

You can check XBIO's fair value in chart for subscribers.

What is the fair value of XBIO stock?

You can check XBIO's fair value in chart for subscribers. The fair value of Xenetic Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Xenetic Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for XBIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Xenetic Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether XBIO is over valued or under valued. Whether Xenetic Biosciences Inc is cheap or expensive depends on the assumptions which impact Xenetic Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XBIO.

What is Xenetic Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 10 2024, XBIO's PE ratio (Price to Earnings) is -1.75 and Price to Sales (PS) ratio is 2.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XBIO PE ratio will change depending on the future growth rate expectations of investors.